Navigation Links
GeneGo Receives SBIR Grant

ST. JOSEPH, Mich., Jan. 12 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today they have been awarded a $336K Phase I SBIR grant from the NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES for creating a novel type of predictive signatures for drug resistance. Under this project GeneGo will develop "regulation signatures" which should overcome many shortcomings of existing methods of molecular diagnostics. For this work GeneGo will utilize its extensive, manually-curated database of signaling interactions and recently developed algorithms for identifying key proteins in signaling networks. The work will be performed in collaboration with the Van Andel Institute for Translational Medicine.  

"What we propose here is the novel concept of using inferred activity of key signaling proteins for building predictive models. Our early results indicate that such models should be significantly more robust than currently available diagnostic applications which are based directly on gene or protein levels. We are very excited about the opportunity provided by NIH support to further develop and validate this approach. If successful, the methodology could be replicated for developing predictive models for sensitivity to a broad range of targeted therapies, leading to a number of diagnostic applications such as specialized molecular tests, systems for formulating combination therapies and procedures for selecting patient cohorts for clinical trials," said Andrej Bugrim, GeneGo COO and PI on the grant.

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscoveryplatform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.0, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.0 is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.

For more information, please visit the company's web site at

SOURCE GeneGo, Inc.



SOURCE GeneGo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
2. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
3. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
4. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
5. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Gram-Negative Bloodstream Pathogens
6. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
7. The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign
8. BASFs Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label
9. CareCentrix Receives URAC Health Utilization Management Accreditation
10. Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
11. SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System
Post Your Comments:
(Date:11/25/2015)... -- The American Academy of Pediatrics (AAP), American Congress ... of Dimes cheered today,s signature into law of ... 2015 (S.799), which takes much-needed strides to ... drugs, such as opioids, and to improve their ... have worked together leading advocacy efforts for its ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... 2015  ARKRAY USA , Inc., ... evidence demonstrating the accuracy of its blood glucose meter ... Resistance, Diabetes and Cardiovascular Disease in Los ... GLUCOCARD ® 01 meter and the Assure ® ... ability to accurately measure glucose levels in blood is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... TyloHelo Inc , North America’s ... Sauna accessories help improve the bather experience in the sauna, and the accessories ... the purist looking for simplicity in design to accessories that encourage a greater ...
(Date:11/25/2015)... TX (PRWEB) , ... November 25, 2015 , ... For ... the companies’ “ Two Organizations, One Beat ” campaign. The partnership between the two ... services to aid in MAP International’s cause. , MAP International was founded in 1954 ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... training center for the Narconon network, announced the release of a new cutting edge ... the Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
(Date:11/25/2015)... ... ... In an ongoing Clinical Study conducted by an independent physician, Andrew Gostine, MD, ... the efficacy of its product and its disinfection protocol. This study is taking place ... through October 2015 at a 360-bed, acute-care, academic medical center located in Chicago, Illinois. ...
Breaking Medicine News(10 mins):